PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2011.43.2.89201143289-95Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast CancerSu Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Imhttp://www.e-crt.org/upload/pdf/crt-43-89.pdf, http://www.e-crt.org/upload/pdf/crt-43-89.pdf
Breast Cancer: Targets and Therapy10.2147/bctt.s97963201673Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerMatthew Grzywacz, Denise Yardleyhttps://www.dovepress.com/getfile.php?fileID=30176
Breast Cancer and Surgery10.5772/intechopen.757592018Management of Hormone Receptor-Positive Metastatic Breast CancerJoanne W. Chiuhttp://www.intechopen.com/download/pdf/60179
Breast Cancer10.1007/s12282-020-01213-w2021283755-764Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic reviewMelika Shirdarreh, Rossanna C. Pezohttps://link.springer.com/content/pdf/10.1007/s12282-020-01213-w.pdf, https://link.springer.com/article/10.1007/s12282-020-01213-w/fulltext.html, https://link.springer.com/content/pdf/10.1007/s12282-020-01213-w.pdf
Breast Cancer and Surgery10.5772/intechopen.765782018Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast CancerFatma Senhttp://www.intechopen.com/download/pdf/61285
Clinical Breast Cancer10.3816/cbc.2007.n.002200776455-464Luteinizing Hormone-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Breast CancerSing-Huang Tan, Antonio C. Wolffhttps://api.elsevier.com/content/article/PII:S152682091170739X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S152682091170739X?httpAccept=text/plain
Clinical Breast Cancer10.1016/j.clbc.2015.09.004201616118-22Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast CancerHope S. Rugohttps://api.elsevier.com/content/article/PII:S1526820915002153?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820915002153?httpAccept=text/plain
Clinical Breast Cancer10.1016/j.clbc.2018.07.0192018186e1381-e1387Clinical Outcomes of Single Versus Double Hormone Receptor–Positive Breast Cancer Patients Treated With Neoadjuvant ChemotherapyJacques Raphael, Alex Kiss, Sharon Nofech-Mozes, Maureen Trudeauhttps://api.elsevier.com/content/article/PII:S1526820918301186?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820918301186?httpAccept=text/plain
Clinical Breast Cancer10.1016/j.clbc.2012.11.0022013133159-166Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer TherapyRowan T. Chlebowskihttps://api.elsevier.com/content/article/PII:S1526820912002583?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820912002583?httpAccept=text/plain
Cancer Management and Research10.2147/cmar.s568022014389Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancerFrancis Arenahttps://www.dovepress.com/getfile.php?fileID=21899